Abstract
Despite major advances in redesigning and producing proteins through recombinant DNA technology, many therapeutic proteins are still produced by extraction from biological tissues or fluids, or from nonrecombinant microorganisms. Modification of such proteins, to improve potency and bioavailability and reduce immunogenicity, can only be carried out post-translationally by chemical-derivatization methods. Genetic- and chemical-modification methods are not mutually exclusive, however, and may be combined to optimize protein-engineering strategies, because chemical modification can introduce structural changes that are not encoded by DNA into both recombinant, and nonrecombinant proteins.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 397-403 |
| Number of pages | 7 |
| Journal | Trends in Biotechnology |
| Volume | 11 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 1993 |
| Externally published | Yes |
ASJC Scopus subject areas
- Biotechnology
- Bioengineering
Fingerprint
Dive into the research topics of 'Chemical derivatization of therapeutic proteins'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS